Neuromuscular DiseasesNCT04473612
Physical Status and Upper Airway Function in Neuromuscular Patients
An observational study of Neuromuscular Diseases and Physical Disability, run by Universidad de Granada at 1 site in Spain.
Trial summary
Inside of studies that report an upper airway function impaired, the upper limb strength has been demonstrated to be determinant in breath, speech and swallow performance. Nevertheless, no previous studies in neuromuscular disease have explored the relation between general disability and upper airway function. Read more about this study
- Who is it for?
- Ages 6 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Neuromuscular Diseases, Physical Disability, Airway Disease
- How many people
- 41 participants
- Where
- 1 siteSpain
- Study dates
- 20 Jul 2020to 1 Sep 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 65 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: Patients diagnosed of neuromuscular disease aged 6-65 years with an impairment of the upper airway, whether in ventilatory, deglutory or communication capacity.
Who may be able to join
- Diagnosis of Neuromuscular disease
- Between 6 and 65 years
- Impairment of the upper airway
- Accepted to sign the informed consent
Who cannot join
- Cognitive impairment.
- Diagnose of autism spectrum disorder or severe intellectual disability
- Physical or functional impairment that limits the performance of evaluation
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Degree Physical Status and Upper Airway Function in Neuromuscular Patients
Inside of studies that report an upper airway function impaired, the upper limb strength has been demonstrated to be determinant in breath, speech and swallow performance. Nevertheless, no previous studies in neuromuscular disease have explored the relation between general disability and upper airway function.
There is a suspicion of upper airway which is associated with physical deterioration, however the extent to which if feeds back has not been explored.
- Conditions
- Neuromuscular Diseases, Physical Disability, Airway Disease
- Medical subject headings
- Neuromuscular Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Neuromuscular low physical status group | Patients diagnosed of Neuromuscular disease with low physical status | |
| Neuromuscular high physical status group | Patients diagnosed of Neuromuscular disease with high physical status | |
| Control group | Healthy subjects |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hand grip strength
Hand grip strength will be evaluated with a pressure dynamometer according to the protocol, to their maximum ability in a seated position . The average of three attempts for the dominant hand will be recorded.
It has been proven that it can be used as an indicator of general health and as a strong predictor of future mortality, disability, falls, complications and resource utilization.
Measured: Baseline
Respiratory function
Respiratory function will be evaluated with spirometry following standardized protocols. Collected variables will be Forced Expiratory Volume in the First Second (FEV1), Forced Vital Capacity (FVC) and Maximal Voluntary Ventilation (MVV).
Measured: Baseline
Peak expiratory flow
Peak expiratory flow is a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. It will be measured following standardized protocols.
Measured: Baseline
Secondary outcomes (16)
European Quality of Life-5 Dimensions (EQ-5D)
The perception of the level of health and the quality of life were evaluated with the questionnaire European Quality of Life-5 Dimensions (EQ-5D). It is composed of 2 parts in which health status is assessed:
- Descriptive system: It consists on 5 dimensions that include mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Patients classify their health status in 3 severity levels: having no problems, having some or moderate problems, being unable to do/having extreme problems.
- Visual Analog Scale, by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).
Measured: Baseline
Fatigue Severity Scale
Fatigue severity scale (FSS) will be used to measure fatigue. It consists of 9 items with answers that the patient scores between 1 and 7. The total is calculated by adding all the items. For children will be used The PedsQL™ Multidimensional Fatigue Scale, which is composed of 18 items comprising 3 dimensions (general fatigue, sleep/rest fatigue, cognitive fatigue), evaluated thorough a Liker scale with values from 0 (never) to 4 (almost always), referring to difficulty presented.
Measured: Baseline
World Health Organization Disability Assessment Scale (WHODAS) 2.0 (WD2)
To measure the degree of disability, the World Health Organization Disability Assessment Scale, WHODAS 2.0 (WD2) will be used. It measures changes in functioning and levels of difficulty in carrying out and carrying out its activities . The WD2 scale is composed of 36 items divided into 6 domains, evaluated through a Likert scale with values from 1 to 5, referring to the difficulty presented. Higher scores show a greater degree of disability.
Measured: Baseline
Activity Limitations in Children and Adults With Neuromuscular Disorders (ACTIVLIM)
The Activity Limitations in Children and Adults With Neuromuscular Disorders (ACTIVLIM) questionnaire is an instrument to measure functional limitation and has been calibrated in children and adults with neuromuscular diseases, according to the difficulty of patients to perform daily activities that require the use of the upper extremities and / or lower.
Measured: Baseline
Brief pain inventory
For pain assessment we will use a specific brief pain questionnaire, Brief Pain Inventory , which consists of three parts. In the first, the patient will indicate in a drawing the area in which he presents this pain. The second part refers to the pain felt in the last days, where it is scored, as in the previous questionnaire, from 0 to 10 (0 being no pain and 10 being the maximum pain felt). Finally, in a third part we see how that pain influences the different activities that the patient performs in his day to day.
Measured: Baseline
Hospital Anxiety and Depression Scale
Anxiety and depression will be assessed with the Hospital Anxiety and Depression Scale (HADS) . This scale is composed of 14 items divided into two subscales, 7 items of anxiety and 7 items of depression, involving higher values worse psycho-emotional state.
Measured: Baseline
Muscle strength of the neck
To evaluate the muscle strength of the neck in neuromuscular patients, neck dynamometry will be performed. With subtests in which front bending, extension, pure lateral flexion, lateral flexion with rotation and pure rotation were measures.
Measured: Baseline
Eating Assessment Tool-10 (EAT-10)
The EAT-10 is a self-administered instrument that evaluate specific symptoms of dysphagia with 10 items and each item have a range from zero (no problem to swallow) to four (a serious problem for life).
In the case of patients pediatric with dysphagia it used Pediatric Eating Assessment Tool (PEDI-EAT-10)
Measured: Baseline
Swallowing quality of life questionnaire (SWAL-QOL)
To measure the possible swallowing problems in daily life we will used the SWAL-QOL, it contains 44 items and each item was scored from zero (the worst state) to four (the best state) . This questionnaire consists of 44 items, consisting of 11 subscales. With a Likert type score in which the patient scores between 1 and 5. Where 1 indicates the worst state and 5 the most favorable.
Measured: Baseline
Functional Oral Intake Scale (FOIS) questionnaire
The severity of swallowing will be assessed using the Functional Oral Intake Scale (FOIS) questionnaire . This scale consists of 7 levels, with 1 being the most severe and 7 being the least severe, the patient has to select the level with which he is.
Measured: Baseline
Karaduman Chewing Performance Scale (KCPS)
There are also questionnaires like Karaduman Chewing Performance Scale (KCPS) , that permitted us evaluate the function of chewing, this test has not been used in previous studies in adults, so in this study we have only used it in the childrens patients.
Measured: Baseline
Orofacial Myofunctional Evaluation with Scores (OMES)
Clinical evaluation of the orofacial myofunctional condition will be evaluated using the Orofacial Myofunctional Evaluation with Scores (OMES) . It consisting of 4 subscales: appearance and posture, mobility and functions (breathing, deglutition, mastication). The examiner attributed scores on a 3 point scale: 3=normal, 2= insufficient ability; and 1= absence of ability or being unable to perform the task.
Measured: Baseline
Volume Viscosity Clinical Exploration Method (MECV-V)
Volume Viscosity Clinical Exploration Method (MECV-V) , this test provides us with information about the volume to which the 5ml, 10ml and 20 ml patients are able to feed and tells us what viscosity, nectar, liquid and pudding. It is used in the diagnosis of oropharyngeal dysphagia.
Measured: Baseline
Voice handicap index (VHI-30)
The phonatory function and it´s repercussion on daily life will be evaluated by the Voice handicap index (VHI-30) . This scale consists of 30 items, consisting of 3 subscales, functional, physical and emotional. In which the patient must indicate the presence or symptoms of dysphonia with a Likert type score of 5 points, in which 0 indicates never and 4 always indicates.
Measured: Baseline
Grade, Roughness, Breathing, Asthenia, Effort (GRBAS)
Perceptual scale of Grade, Roughness, Breathing, Asthenia, Effort (GRBAS) . Will be used to analyze qualitative aspects of the voice, it is completed by the evaluator who qualifies as: 0 normal, 1 mild, 2 moderate, 3 severe, each quality of the voice (Degree of dysphonia, scratchy, blown, weak or asthenic, tight or strangled).
Measured: Baseline
Functional evaluation of the voice
The functional evaluation of the voice will allow us to measure the intensity, frequency and duration of the voice: To evaluate the intensity of the voice, measured in decibels (dB), we will use a sound level meter; To evaluate the frequency of the voice , measured in Hz (Hz), we use the PRAAT software (Praat from the Dutch "speak"). In addition, the duration of the phonation and breathing times , measured in Sg, will be evaluated, for this we use an audio recorder.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2020
- Study start20 Jul 2020
- Primary completion15 Aug 2020
- Study completion1 Sep 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuromuscular DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 41 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad de Granada
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marie Carmen Valenza, Universidad de Granada
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04473612
- Sponsor's protocol ID
- DF0091UG
- Status last verified
- Oct 2020
- First submitted
- 8 Jul 2020
- Last updated
- 14 Oct 2020
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Degree Physical Status and Upper Airway Function in Neuromuscular Patients
- ClinicalTrials.gov ID
- NCT04473612
- Acronym / sponsor ID
- DF0091UG
- Conditions
- Neuromuscular Diseases, Physical Disability, Airway Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 41 participants (actual)
- Lead sponsor
- Universidad de GranadaUniversity, hospital or other
- Study start
- 20 Jul 2020 (actual)
- Primary completion
- 15 Aug 2020 (actual)
- Study completion
- 1 Sep 2020 (actual)
- First posted
- 16 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Inside of studies that report an upper airway function impaired, the upper limb strength has been demonstrated to be determinant in breath, speech and swallow performance. Nevertheless, no previous studies in neuromuscular disease have explored the relation between general disability and upper airway function.
There is a suspicion of upper airway which is associated with physical deterioration, however the extent to which if feeds back has not been explored.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Neuromuscular low physical status group | – | –Patients diagnosed of Neuromuscular disease with low physical status |
| Neuromuscular high physical status group | – | –Patients diagnosed of Neuromuscular disease with high physical status |
| Control group | – | –Healthy subjects |
Who may qualify
- Ages
- 6 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients diagnosed of neuromuscular disease aged 6-65 years with an impairment of the upper airway, whether in ventilatory, deglutory or communication capacity.
Key inclusion criteria (4 listed)
- Diagnosis of Neuromuscular disease
- Between 6 and 65 years
- Impairment of the upper airway
- Accepted to sign the informed consent
Key exclusion criteria (3 listed)
- Cognitive impairment.
- Diagnose of autism spectrum disorder or severe intellectual disability
- Physical or functional impairment that limits the performance of evaluation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Hand grip strength
Time frame: Baseline
Hand grip strength will be evaluated with a pressure dynamometer according to the protocol, to their maximum ability in a seated position . The average of three attempts for the dominant hand will be recorded. It has been proven that it can be used as an indicator of general health and as a strong predictor of future mortality, disability, falls, complications and resource utilization.
Respiratory function
Time frame: Baseline
Respiratory function will be evaluated with spirometry following standardized protocols. Collected variables will be Forced Expiratory Volume in the First Second (FEV1), Forced Vital Capacity (FVC) and Maximal Voluntary Ventilation (MVV).
Peak expiratory flow
Time frame: Baseline
Peak expiratory flow is a person's maximum speed of expiration, as measured with a peak flow meter, a small, hand-held device used to monitor a person's ability to breathe out air. It will be measured following standardized protocols.
16 secondary outcomes
European Quality of Life-5 Dimensions (EQ-5D)
Time frame: Baseline
Fatigue Severity Scale
Time frame: Baseline
World Health Organization Disability Assessment Scale (WHODAS) 2.0 (WD2)
Time frame: Baseline
Activity Limitations in Children and Adults With Neuromuscular Disorders (ACTIVLIM)
Time frame: Baseline
Brief pain inventory
Time frame: Baseline
Hospital Anxiety and Depression Scale
Time frame: Baseline
Muscle strength of the neck
Time frame: Baseline
Eating Assessment Tool-10 (EAT-10)
Time frame: Baseline
Swallowing quality of life questionnaire (SWAL-QOL)
Time frame: Baseline
Functional Oral Intake Scale (FOIS) questionnaire
Time frame: Baseline
Karaduman Chewing Performance Scale (KCPS)
Time frame: Baseline
Orofacial Myofunctional Evaluation with Scores (OMES)
Time frame: Baseline
Volume Viscosity Clinical Exploration Method (MECV-V)
Time frame: Baseline
Voice handicap index (VHI-30)
Time frame: Baseline
Grade, Roughness, Breathing, Asthenia, Effort (GRBAS)
Time frame: Baseline
Functional evaluation of the voice
Time frame: Baseline
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2020.
- Individual participant dataSharing planned: No
Related trials for Neuromuscular Diseases
RecruitingPhase 2/3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
RecruitingObservational study
Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced Peripheral Neuropathy (CIPN), Healthy
Enrolling by invitationPhase 2/3
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis, gMG
Not yet recruitingPhase 2
A Phase 2 Trial to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tegacorat in Male Participants 4 to <7 Years of Age With Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD)
RecruitingPhase 3
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Myasthenia Gravis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Neuromuscular Diseases and Physical Disability, run by Universidad de Granada at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Oct 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hand grip strength (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2020.